An novel single dose regimen of tremelimumab combined with durvalumab could be a way to treat unresectable hepatocellular carcinoma. In this recently published Clinical Cancer Research study, co-authored by Certara’s Rajesh Krishna, the findings reveal that overall survival was longer for patients given this drug regimen.
If a new drug or medical device receives a positive evaluation from a national payer, that doesn’t automatically mean that the product will be used locally. The product must be registered on a formulary or selected by a purchasing center first. Successful payer engagement at the local level requires effective value communication. Recent innovations in … Continued
抗体薬物複合体（ADC）は、腫瘍細胞を消滅させるユニークな方法であり、単独療法であれ併用療法であれ、腫瘍学において十分に利用されていない免疫治療薬の選択肢です。ADCの最初のFDA承認は2011年でした... ADC development is inherently challenging because it … Continued
米国国立糖尿病・消化器・腎臓病研究所は、非アルコール性脂肪性肝疾患（NAFLD）を肝臓に過剰な脂肪が蓄積された状態とみなし、非アルコール性脂肪性肝炎（NASH）をNAFLDの一種としています。肥満と 2 型糖尿病はNAFLD発症のリスクが高いようです。Many innovative and scientifically intriguing … Continued
Immunotherapy presents interesting and proximally viable therapeutic options in the growing armamentarium of treatment modalities to combat complex, multifactorial diseases. Indeed, its revolution within oncology is astounding. The field has witnessed rampant and clinically significant advances, with the approval of several checkpoint inhibitors. Clinical trials with these inhibitors suggest that there are more robust and … Continued
This blog asks and answers 10 critical drug development questions whether you have a new molecular entity or are repurposing a drug already in clinical use.
